P775 Efficacy and safety of risankizumab in children with Crohn’s disease: A preliminary report

E Spencer,R Stein,T Shalem,E Zifman,M Dubinsky,R Lev Tzion,D Turner,A Assa

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0905

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Risankizumab (RISA) is a selective p19 anti-interleukin (IL)-23 antibody approved for adults with Crohn’s disease (CD) and for children ≥ 16 years in selected countries. Given delays in pediatric approvals, we aimed to assess the real-world effectiveness and safety of RISA in pediatric patients with CD. Methods From September 2022 to November 2023, all pediatric patients (<18 years) with refractory CD treated with RISA in 5 centers from US and Israel were retrospectively included. All received a 600 mg RISA intravenous induction at weeks 0-4-8. Patients completing the induction phase were treated with subcutaneous injection of 360mg at week 12 and every 8 weeks thereafter. The primary endpoint was steroid-free clinical remission (SFR) after 3 intravenous infusions (i.e., wPCDAI ≤12.5). Secondary endpoints included clinical response (i.e., >17.5-point decrease of wPCDAI), biochemical remission (CRP ≤ 5 mg/L) and drug sustainability. Adverse events were explicitly recorded. Results Included were 23 children [13 (56%) males; mean age at diagnosis 14.1±3.7 years, median disease duration 3.9 (IQR 2.6-7.7) years, 11 (48%) < 16 years of age] with a median follow-up period of 21 weeks (IQR 9.4-44.2) (Table 1). All had failed at least one previous biologic treatment and 18 (78%) failed two, including 15 (65%) with prior ustekinumab treatment. After 3 infusions, SFR was observed in 15 (65%) children, clinical remission in 16 (70%), clinical response in 17 (74%), and CRP remission in 17 (74%). There was no difference in response rate of patients <16 years (64% SFR). In a subgroup analysis of 15 patients with prior ustekinumab exposure, SFR was observed in 11 (73%). Only two patients discontinued RISA during follow-up, one who was in clinical and CRP remission at week 12, due to loss of follow-up and the other due to occurrence of an intra-abdominal abscess. Ten patients completed 6 months follow-up, of whom 8 (80%) achieved SFR by then. Only one disease-related adverse event occurred in one patient (intra-abdominal abscess). No drug-related adverse events were recorded. Conclusion While awaiting pediatric registration trials, our preliminary data suggest that RISA is safe and effective in inducing and maintaining remission in children with highly-refractory CD. This includes also children previously failing ustekinumab and children younger than 16 years.

gastroenterology & hepatology